NO975492L - Preparat for dignostisering av metabolsk syndrom samt sykdommer som omfatter syndromet - Google Patents

Preparat for dignostisering av metabolsk syndrom samt sykdommer som omfatter syndromet

Info

Publication number
NO975492L
NO975492L NO975492A NO975492A NO975492L NO 975492 L NO975492 L NO 975492L NO 975492 A NO975492 A NO 975492A NO 975492 A NO975492 A NO 975492A NO 975492 L NO975492 L NO 975492L
Authority
NO
Norway
Prior art keywords
syndrome
metabolic syndrome
dignostization
preparation
well
Prior art date
Application number
NO975492A
Other languages
English (en)
Other versions
NO975492D0 (no
NO319829B1 (no
Inventor
Per Maarin
Original Assignee
Cortendo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortendo Ab filed Critical Cortendo Ab
Publication of NO975492D0 publication Critical patent/NO975492D0/no
Publication of NO975492L publication Critical patent/NO975492L/no
Publication of NO319829B1 publication Critical patent/NO319829B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Combined Controls Of Internal Combustion Engines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO19975492A 1995-05-30 1997-11-28 Preparat for diagnostisering av metabolsk syndrom samt sykdommer som omfatter syndromet NO319829B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9501991A SE505391C2 (sv) 1995-05-30 1995-05-30 Användning av kortisol-agonister för framställning av ett system för diagnostisering av det metabola syndromet
PCT/SE1996/000708 WO1996038179A1 (en) 1995-05-30 1996-05-30 Preparation for diagnostic of the metabolic syndrome and diseases including the syndrome

Publications (3)

Publication Number Publication Date
NO975492D0 NO975492D0 (no) 1997-11-28
NO975492L true NO975492L (no) 1998-01-27
NO319829B1 NO319829B1 (no) 2005-09-19

Family

ID=20398470

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19975492A NO319829B1 (no) 1995-05-30 1997-11-28 Preparat for diagnostisering av metabolsk syndrom samt sykdommer som omfatter syndromet

Country Status (16)

Country Link
US (1) US6410339B1 (no)
EP (1) EP0835138B1 (no)
JP (1) JPH11505850A (no)
CN (1) CN1078479C (no)
AT (1) ATE235258T1 (no)
AU (1) AU716671B2 (no)
BR (1) BR9608683A (no)
CA (1) CA2222215A1 (no)
DE (1) DE69626982T2 (no)
DK (1) DK0835138T3 (no)
ES (1) ES2189872T3 (no)
NO (1) NO319829B1 (no)
PT (1) PT835138E (no)
RU (1) RU2171471C2 (no)
SE (1) SE505391C2 (no)
WO (1) WO1996038179A1 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217505B2 (en) * 1998-02-26 2007-05-15 Cortendo Ab Method for determining whether condition is symptom of metabolic syndrome
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
RU2367950C2 (ru) * 2005-03-28 2009-09-20 Ижевский государственный технический университет Способ прогнозирования развития метаболического синдрома при артериальной гипертонии у мужчин
US20090117660A1 (en) * 2005-04-30 2009-05-07 Oakville Hong Kong Co., Limited Devices and methods for sample collection and analysis
RU2321354C2 (ru) * 2006-04-21 2008-04-10 Анатолий Николаевич Дмитриев Способ диагностики стадий метаболического синдрома
US20100196880A1 (en) * 2006-10-06 2010-08-05 Ebenezer Satyaraj Compositions and multiplex assays for measuring biological mediators of physiological health
RU2336807C1 (ru) * 2007-05-30 2008-10-27 Виктория Борисовна Мычка Способ диагностики метаболического синдрома
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
RU2403868C1 (ru) * 2009-07-07 2010-11-20 Учреждение Российской академии медицинских наук Дальневосточный научный центр физиологии и патологии дыхания Сибирского отделения Российской академии медицинских наук (ДНЦ ФПД СО РАМН) Способ оценки риска развития метаболического синдрома у больных хроническим холециститом
RU2444298C1 (ru) * 2010-07-15 2012-03-10 Учреждение Российской академии медицинских наук Научный центр клинической и экспериментальной медицины Сибирского отделения РАМН (НЦКЭМ СО РАМН) Способ диагностики метаболического синдрома
CN105973881A (zh) * 2016-04-27 2016-09-28 樊福好 一种检测机体活度的溶液及检测方法

Also Published As

Publication number Publication date
MX9709234A (es) 1998-10-31
US6410339B1 (en) 2002-06-25
SE505391C2 (sv) 1997-08-18
AU5917396A (en) 1996-12-18
SE9501991D0 (sv) 1995-05-30
RU2171471C2 (ru) 2001-07-27
CA2222215A1 (en) 1996-12-05
CN1185743A (zh) 1998-06-24
BR9608683A (pt) 1999-12-07
EP0835138B1 (en) 2003-03-26
PT835138E (pt) 2003-08-29
NO975492D0 (no) 1997-11-28
ES2189872T3 (es) 2003-07-16
DK0835138T3 (da) 2003-07-21
SE9501991L (sv) 1996-12-01
DE69626982T2 (de) 2004-03-04
JPH11505850A (ja) 1999-05-25
ATE235258T1 (de) 2003-04-15
NO319829B1 (no) 2005-09-19
CN1078479C (zh) 2002-01-30
EP0835138A1 (en) 1998-04-15
DE69626982D1 (de) 2003-04-30
WO1996038179A1 (en) 1996-12-05
AU716671B2 (en) 2000-03-02

Similar Documents

Publication Publication Date Title
NO975492D0 (no) Preparat for dignostisering av metabolsk syndrom samt sykdommer som omfatter syndromet
Uribarri et al. Association of acidosis and nutritional parameters in hemodialysis patients
Yokoe et al. Intermittent hypoxia reverses the diurnal glucose rhythm and causes pancreatic β‐cell replication in mice
da Silva Alexandre et al. Prevalence and associated factors of sarcopenia among elderly in Brazil: findings from the SABE study
Nutt et al. Effect of long-term therapy on the pharmacodynamics of levodopa: relation to on-off phenomenon
Harris et al. Associations of fat distribution and obesity with hypertension in a bi‐ethnic population: the ARIC study
Zieman et al. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension
Shin et al. Carotid body denervation prevents fasting hyperglycemia during chronic intermittent hypoxia
Saladini et al. Isolated systolic hypertension of young-to-middle-age individuals implies a relatively low risk of developing hypertension needing treatment when central blood pressure is low
Charloux et al. Sleep deprivation blunts the night time increase in aldosterone release in humans
Chowdhury et al. Elevated glycated haemoglobin in non-diabetic patients is associated with an increased mortality in myocardial infarction
Bunsawat et al. The effect of acute maximal exercise on postexercise hemodynamics and central arterial stiffness in obese and normal‐weight individuals
Schwartz et al. Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy
RU97121292A (ru) Препарат для диагностики метаболического синдрома и заболеваний, включающих в себя данный синдром
Lee et al. Retinoic acid alleviates C on A‐induced hepatitis and differentially regulates effector production in NKT cells
Bullock et al. A phase 1 double‐blind, placebo‐controlled study of zuranolone (SAGE‐217) in a phase advance model of insomnia in healthy adults
Chung et al. Daytime glycemic variability and frailty in older patients with diabetes: a pilot study using continuous glucose monitoring
Liu et al. Asymmetry of habitual 24-hour intraocular pressure rhythm in glaucoma patients
Alinezhad‐Namaghi et al. Association of time‐restricted feeding, arterial age, and arterial stiffness in adults with metabolic syndrome
Khaledifar et al. Association between salt intake and albuminuria in normotensive and hypertensive individuals
Lombardi et al. Periodic limb movements during sleep and blood pressure changes in sleep apnoea: Data from the European Sleep Apnoea Database
WO2005117937A3 (en) Alpha-1- acid glycoprotein for the treatment of diabetes
Levi Methodological considerations in psychoendocrine research
Del Seppia et al. Evidence in hypertensive rats of hypotensive effect after mandibular extension
Möhrenschlager et al. Effect of penicillin G on corium thickness in linear morphea of childhood: an analysis using ultrasound technique